Abiopharma

🔍 Silver Point Capital L.P. (Executive)

Company: Keenova Therapeutics plc (NONE)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 250,000 shares of Common Stock at $92.25 per share (Direct)
  Date: 2026-01-07 | Code: P | equity_swap_involved: false | shares_owned_after: 4,952,714.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Silver Point Capital, L.P. ("Silver Point") or its wholly owned subsidiaries are the investment managers of Silver Point Capital Fund, L.P., Silver Point Capital Offshore Master Fund, L.P., Silver Point Distressed Opportunity Institutional Partners, L.P., Silver Point Distressed Opportunity Institutional Partners Master Fund (Offshore), L.P., Silver Point Distressed Opportunities Fund, L.P., Silver Point Distressed Opportunities Offshore Master Fund, L.P., Silver Point Distressed Opportunity Institutional Partners II, L.P. and Silver Point Distressed Opportunity Institutional Partners II (Offshore), L.P. (the "Funds") and, by reason of such status, may be deemed to be the beneficial owner of all the reported securities held by the Funds.
• F2: (Continued from footnote 1) Silver Point Capital Management, LLC ("Management") is the general partner of Silver Point and as a result may be deemed to be the beneficial owner of all securities held by the Funds. Messrs. Edward A. Mule and Robert J. O'Shea are each members of Management and as a result may be deemed to be the beneficial owner of all of the securities held by the Funds. Messrs. Mule and O'Shea disclaim beneficial ownership of the reported securities held by Funds except to the extent of their pecuniary interests.